RxDoctor Payments Data

Catherine Byrne, APRN

Nurse Practitioner · Tampa, FLNPI 1295403129

Payments from drug & device makers

$1,747in general payments, 2019–2025

Across 12 payments — averaging $145.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmaessentia USA Corporation$460
  • Syndax Pharmaceuticals, Inc.$291
  • Incyte Corporation$274
  • E.r. Squibb & Sons, L.L.C.$216
  • Sobi, Inc$144
  • Rigel Pharmaceuticals, Inc.$125
  • plus $237 from 2 others

What the payments were for

  • Speaking & faculty fees$46026%
  • Food & beverage$1,28774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,747 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$41,614
Medicare patients
144
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XospataGilteritinib Fumarate14$280,976
BesremiRopeginterferon Alfa-2b-Njft13$214,624
InqoviDecitabine/Cedazuridine23$185,661
TasignaNilotinib Hcl11$110,316
Cyclosporine ModifiedCyclosporine, Modified26$1,323
Hydroxyurea20$520
Acyclovir24$422
Fluconazole11$268
Levofloxacin21$245
Allopurinol32$186
Ondansetron Hcl12$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmaessentia USA CorporationBesremi$460$214,62413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →